CL2015000889A1 - Compounds derived from [ortho bi- (hetero-) aryl] - [2- (meta bi- (hetero-) aryl) -pyrrolidin-1-yl] -methanone, as orexin receptor antagonists; pharmaceutical composition that includes them; and its use in the prevention or treatment of mental health diseases or disorders related to orexinergic dysfunctions. - Google Patents

Compounds derived from [ortho bi- (hetero-) aryl] - [2- (meta bi- (hetero-) aryl) -pyrrolidin-1-yl] -methanone, as orexin receptor antagonists; pharmaceutical composition that includes them; and its use in the prevention or treatment of mental health diseases or disorders related to orexinergic dysfunctions.

Info

Publication number
CL2015000889A1
CL2015000889A1 CL2015000889A CL2015000889A CL2015000889A1 CL 2015000889 A1 CL2015000889 A1 CL 2015000889A1 CL 2015000889 A CL2015000889 A CL 2015000889A CL 2015000889 A CL2015000889 A CL 2015000889A CL 2015000889 A1 CL2015000889 A1 CL 2015000889A1
Authority
CL
Chile
Prior art keywords
hetero
aryl
methanone
pyrrolidin
ortho
Prior art date
Application number
CL2015000889A
Other languages
Spanish (es)
Inventor
Markus Gude
Christoph Boss
Christine Brotschi
Bibia Heidmann
Thierry Sifferlen
Martin Bolli
Jodi T Williams
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CL2015000889A1 publication Critical patent/CL2015000889A1/en

Links

CL2015000889A 2012-10-10 2015-04-08 Compounds derived from [ortho bi- (hetero-) aryl] - [2- (meta bi- (hetero-) aryl) -pyrrolidin-1-yl] -methanone, as orexin receptor antagonists; pharmaceutical composition that includes them; and its use in the prevention or treatment of mental health diseases or disorders related to orexinergic dysfunctions. CL2015000889A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12880199 2012-10-10
EP13157809 2013-03-05

Publications (1)

Publication Number Publication Date
CL2015000889A1 true CL2015000889A1 (en) 2015-07-10

Family

ID=57232543

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015000889A CL2015000889A1 (en) 2012-10-10 2015-04-08 Compounds derived from [ortho bi- (hetero-) aryl] - [2- (meta bi- (hetero-) aryl) -pyrrolidin-1-yl] -methanone, as orexin receptor antagonists; pharmaceutical composition that includes them; and its use in the prevention or treatment of mental health diseases or disorders related to orexinergic dysfunctions.

Country Status (1)

Country Link
CL (1) CL2015000889A1 (en)

Similar Documents

Publication Publication Date Title
LTPA2018511I1 (en) Polycyclic carbamoylpyridine compounds and their pharmaceutical use
IL239355A0 (en) Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
HK1210030A1 (en) Sulfamoyl aryamides and the use thereof as medicaments for the treatment of hepatitis b
EP2827856A4 (en) Compounds and compositions for the treatment of muscular disorders
IL214208A (en) Substituted bicyclic heterocyclic compounds, pharmaceutical compositions containing them and their use in inhibiting the jak pathway
DK3444261T3 (en) 2,2-DIFLUOROPROPIONAMIDE DERIVATIVE OF BARDOXOLONE METHYL, PHARMACEUTICAL COMPOSITIONS AND POLYMORPHES THEREOF FOR USE IN THE TREATMENT OF CERTAIN DISORDERS
HK1207304A1 (en) Crhr1 antagonists for use in the treatment of patients having crh overactivity crh crhr1
DK2800581T3 (en) APPROACHES TO THE TREATMENT OF BEHAVIORAL SYMPTOMS OF NEUROLOGICAL AND MENTAL DISORDERS
DK3040336T3 (en) Compounds for use in the treatment of TYK2 Kinase-mediated conditions
HK1207860A1 (en) 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders 2--5---2h--3-
HK1198909A1 (en) Compositions and methods for the treatment of hepatic diseases and disorders
CL2014003325A1 (en) Compounds derived from difluoro-hexahydro-cyclopentaoxacinyls and difluoro-hexahydro-benzooxacinyls, bace 1 inhibitors; pharmaceutical composition; and its use in the treatment of diseases with elevated levels of beta-amyloid, such as Alzheimer's disease
EP2897621A4 (en) Compounds and compositions for use in the prevention and treatment of inflammation-related disorders, pain and fever, skin disorders, cancer and precancerous conditions thereof
HK1205467A1 (en) Pharmaceutical composition for the prophylaxis and treatment of psychological, behavioral and cognitive disorders
GB201511770D0 (en) Novel pharmaceutical formulationsand their use in the treatment of periodontal disease
HK1215794A1 (en) Allogeneic autophagosome-enriched composition for the treatment of disease
HK1197235A1 (en) Dihydropyrazoles, pharmaceutical compositions thereof and their use for the treatment of fertility disorders
HUE037179T2 (en) Pharmaceutical compositions for the treatment of muscular disorders
IL238461A0 (en) 1 h-indole-3-carboxamide derivatives and use thereof as p2y12 antagonists
IL234093A0 (en) Oral unit dosage forms and uses of same for the treatment of gaucher disease
IL234616A0 (en) Herbal composition for the treatment of metabolic disorders
CL2015000889A1 (en) Compounds derived from [ortho bi- (hetero-) aryl] - [2- (meta bi- (hetero-) aryl) -pyrrolidin-1-yl] -methanone, as orexin receptor antagonists; pharmaceutical composition that includes them; and its use in the prevention or treatment of mental health diseases or disorders related to orexinergic dysfunctions.
GB201207102D0 (en) CRHR1 antagonists for use in the treatment of patients having CRH overactivity
TH134234B (en) Pyrazine derivatives and their use in the treatment Of normal nervous disorders
TH164734B (en) Spiro-oxindol compounds And the use of these substances as therapeutic agents